Using statins to reduce heart problems in breast cancer patients receiving HER2 therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 study investigates whether adding statins can help prevent cardiac toxicity in women with Stage I-III HER2 positive breast cancer undergoing anti-HER2 treatment. It is a single-arm, open-label trial that aims to assess the cardioprotective effects of Lipitor (40mg) in this patient population. The study will monitor treatment delays and discontinuations due to cardiac dysfunction, with the ultimate goal of improving patient outcomes and quality of life during cancer therapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically and/or cytologically confirmed diagnosis of Stage I-III female breast cancer (including inflammatory breast cancer)
* Scheduled to receive neoadjuvant/adjuvant HER2 targeted therapy
* Between ≥18 years of age
* Female patients of childbearing potential must have a negative pregnancy test (serum or urine) prior to enrollment. Female patients must agree to use effective barrier contraception during the period of therapy
* Baseline LVEF ≥ 50%
* Prior cancers allowed if no evidence of disease in last 5 years
* ECOG 0-2
* No prior history of treatment with HER2 targeted therapy or anthracyclines based chemotherapy
* Adequate bone marrow function:

I. ANC ≥ 1000/uL II. platelet count ≥ 100,000/uL III. hemoglobin ≥ 9.0 g/dL

• Adequate hepatic function: I. Total bilirubin ≤ 1.5 X ULN II. AST (SGOT) ≤ 5 X ULN III. ALT (SGPT) ≤ 5 X ULN

* Adequate renal function, Creatinine \< 1.5x institutional ULN or calculated creatinine clearance ≥ 50 mL/min as estimated using the Cockcroft-Gault formula
* Ability to understand the nature of this study protocol and give written informed consent
* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

Exclusion Criteria:

* Participants with stage IV breast cancer
* Participants currently taking statins
* Uncontrolled hypertension (systolic blood pressure \>190 mm Hg or diastolic blood pressure \>100 mm Hg)
* No active liver disease
* Current use of CYP 3A4 inhibitors
* Any condition including the presence of laboratory abnormalities, which, in the opinion of the investigator places the subject at unacceptable risk if he/she were to participate in the study
* Life expectancy \< 12 weeks
* Pregnancy (positive pregnancy test) or lactation
* Pre-existing sensory neuropathy \> grade one
* Has significant cardiovascular disease, such as:

LVEF \< 50% at baseline as assessed by ECHO (preferred) i) Class III or Class IV myocardial disease as described by the New York Heart Association ii) Recent history (within 6 months prior to enrollment) of myocardial infarction; or iii) Symptomatic arrhythmia at the time of randomization

* Major surgery without complete recovery in the past four weeks prior to screening
* Concurrent active infection
* Participant with uncontrolled and/ or active infection with HIV, Hepatitis B or Hepatitis C
* Participant who has a history of allergy or hypersensitivity to any of the study drugs
* Participant with a history of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, interstitial pulmonary fibrosis, pulmonary hypersensitivity pneumonitis
* Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study

Where it's running

• Trinitas Hospital and Comprehensive Cancer Center
  Elizabeth, New Jersey, United States Recruiting
• RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton
  Hamilton, New Jersey, United States Recruiting
• RWJBarnabas Health - - Jersey City Medical Medical
  Jersey City, New Jersey, United States Recruiting
• Monmouth Medical Center Southern Campus
  Lakewood, New Jersey, United States Recruiting
• RWJBarnabas Health - Monmouth Medical Center
  Long Branch, New Jersey, United States Recruiting
• Monmouth Community Medical
  Long Branch, New Jersey, United States Recruiting

Study contacts

• Principal investigator: Mridula George, MD — Rutgers Cancer Institute of New Jersey
• Study coordinator: Mridula George, MD
• Email: mridula@cinj.rutgers.edu
• Phone: 732-235-9081

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• One-week versus three-week partial breast irradiation for early-stage breast cancer

  This trial tests whether a shorter one-week partial breast irradiation plan is not worse than a three-week plan for women after breast-conserving surgery.

  Recruiting Fudan University · Shanghai · NCT07832279

• Culmerciclib with endocrine therapy before surgery for early HER2-negative hormone receptor-positive breast cancer

  This trial tests whether adding culmerciclib to an aromatase inhibitor before surgery helps women with certain early breast cancers better shrink tumors than an aromatase inhibitor alone.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07796880

• Partial Breast Radiation After Breast-Conserving Surgery Without Sentinel Node Biopsy

  This pilot study tests whether partial breast irradiation is safe for women who had breast-conserving surgery without sentinel lymph node biopsy or axillary dissection.

  Recruiting NYU Langone Health · New York, New York · NCT07723209

• CDK4/6 inhibitors with endocrine therapy before surgery for HR+/HER2- high-risk early breast cancer

  This study tests whether adding a CDK4/6 inhibitor to endocrine therapy before surgery can help guide safer de-escalation of chemotherapy using ctDNA as a marker.

  Recruiting Phase 2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT07366112

• Exercise and Quality of Life for Early-Stage Hormone Receptor–Positive/HER2-Negative Breast Cancer on Adjuvant Therapy

  This Spain-based trial tests whether a combined resistance and aerobic exercise program improves quality of life for women with early-stage HR+/HER2− breast cancer who are on adjuvant endocrine therapy, with or without a CDK4/6 inhibitor.

  Recruiting at 3 sites Spanish Breast Cancer Research Group · L'Hospitalet de Llobregat, Barcelona and 4 other locations · NCT07215364

• Using blood-based tumor DNA (ctDNA) to find leftover breast cancer after treatment

  This research will test whether a simple blood test that looks for tiny bits of tumor DNA can tell if people treated for breast cancer (including HR+/HER2-, HER2+, and triple-negative) still have leftover cancer or are at risk of recurrence.

  Recruiting at 16 sites Tempus AI · Birmingham, Alabama and 15 other locations · NCT07211178

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.